Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients

Lawrence F Eichenfield; Boni Elewski; Jeffrey L Sugarman; Ted Rosen; Aditya Gupta; Wendy Cantrell; Radhakrishnan Pillai; Abby Jacobson

doi:10.25251/skin.4.supp.60

Lawrence F Eichenfield
Boni Elewski
Jeffrey L Sugarman
Ted Rosen
Aditya Gupta
Wendy Cantrell
Radhakrishnan Pillai
Abby Jacobson

Keywords

Onychomycosis, Pediatrics, Efinaconazole, Topical, Safety, Pharmacokinetics, Efficacy

Abstract

Abstract not available.

References

1. Gupta AK, et al. Pediatr Dermatol. 2018;35(5):552-559.

2. Rodriguez-Pazos L, et al. Mycoses. 2011;54(5):450-453.

3. Eichenfield LF, Friedlander SF. J Drugs Dermatol. 2017;16(2):105-109.

4. Prescribing Information. JUBLIA® (efinaconazole) topical solution, 10%. Ortho Dermatologics.

Poster PDF

Published

Sep 2, 2020

DOI https://doi.org/10.25251/skin.4.supp.60

How to Cite

[1]

Eichenfield, L.F., Elewski, B., Sugarman, J.L., Rosen, T., Gupta, A., Cantrell, W., Pillai, R. and Jacobson, A. 2020. Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients. SKIN The Journal of Cutaneous Medicine. 4, 5 (Sep. 2020), s61. DOI:https://doi.org/10.25251/skin.4.supp.60.

Issue

Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)

Section

Nail Unit Disorders

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Meredith Burns, Timothy Orlowski, Hoang Ho-Pham, Carly Elston, Boni Elewski, New Onset Generalized Pustular Psoriasis Rapidly Improved with IL-36 Blockade , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 1 (2023)
Linda Stein Gold, Mark Lebwohl, Neal Bhatia, Douglas DiRuggiero, Abby Jacobson, Radhakrishnan Pillai, Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, Jonathan S Weiss, Lawrence Green, Leon Kircik, Lauren Miller, Abby Jacobson, Susan Harris, Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12% , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Mark Lebwohl, Andrew Blauvelt, Alan Menter, Kim Papp, Abby Jacobson, Long-term Efficacy, Safety, and Patient-Reported Outcomes in a Phase 2 Study of Brodalumab , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Mark Lebwohl, Andrea Murina, George Han, Abby Jacobson, Brodalumab: 4-Year US Pharmacovigilance Report , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Mark Lebwohl, Kim A Papp, Jashin J Wu, Andrew Blauvelt, Alan Menter, Shipra Rastogi, Radhakrishnan Pillai, Robert Israel, Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Stephan Weidinger, Jonathan Silverberg, Darryl Toth, Thomas Bieber, Andrew Alexis, Boni Elewski, Andrew Pink, DirkJan Hignen, Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, MD, Leon H. Kircik, MD, Emil A Tanghetti, MD, Hilary Baldwin, MD, Zoe D. Draelos, MD, Michael Gold, MD, Edward Lain, MD, MBA, David M Pariser, MD, Neil Sadick, MD, Radhakrishnan Pillai, PhD, Varsha Bhatt, PhD, Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Randomized Phase 2 and Phase 3 Studies of the First Triple-Combination Drug , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Lawrence Green, Jerry Bagel, George Han, Abby Jacobson, Martha Sikes, Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis: Epidermal Permeation, Efficacy, and Safety , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Alan Menter, Jeff Sobell, Jonathan I Silverberg, Mark Lebwohl, Shipra Rastogi, Radhakrishnan Pillai, Robert J Israel, Long-Term Efficacy of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: Data from a Pivotal Phase 3 Clinical Trial , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii

1 2 3 4 5 6 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)